Refinement of screening for familial pancreatic cancer by Bartsch, D.K. et al.
ORIGINAL ARTICLE
Refinement of screening for familial pancreatic cancer
D K Bartsch,1 E P Slater,1 A Carrato,2 I S Ibrahim,3 C Guillen-Ponce,2 H F A Vasen,3
E Matthäi,1 J Earl,2 F S Jendryschek,1 J Figiel,4 M Steinkamp,5 A Ramaswamy,6
E Vázquez-Sequeiros,7 M Muñoz-Beltran,8 J Montans,9 E Mocci,2 B A Bonsing,10
M Wasser,11 G Klöppel,12 P Langer,1,13 V Fendrich,1 T M Gress5
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
gutjnl-2015-311098).
For numbered affiliations see
end of article.
Correspondence to
Dr D K Bartsch, Department of





Received 14 November 2015
Revised 29 April 2016
Accepted 1 May 2016
Published Online First
24 May 2016
To cite: Bartsch DK,
Slater EP, Carrato A, et al.
Gut 2016;65:1314–1321.
ABSTRACT
Objective Surveillance programmes are recommended
for individuals at risk (IAR) of familial pancreatic cancer
(FPC) to detect early pancreatic cancer (pancreatic ductal
adenocarcinoma, PDAC). However, the age to begin
screening and the optimal screening protocol remain to
be determined.
Methods IAR from non-CDKN2A FPC families
underwent annual screening by MRI with endoscopic
ultrasonography (EUS) in board-approved prospective
screening programmes at three tertiary referral centres.
The diagnostic yield according to age and different
screening protocols was analysed.
Results 253 IAR with a median age of 48
(25–81) years underwent screening with a median of
3 (1–11) screening visits during a median follow-up of
28 (1–152) months. 134 (53%) IAR revealed pancreatic
lesions on imaging, mostly cystic (94%), on baseline or
follow-up screening. Lesions were significantly more
often identified in IAR above the age of 45 years
(p<0.0001). In 21 IAR who underwent surgery, no
significant lesions (PDAC, pancreatic intraepithelial
neoplasia (PanIN) 3 lesions, high-grade intraductal
papillary mucinous neoplasia (IPMN)) were detected
before the age of 50 years. Potentially relevant lesions
(multifocal PanIN2 lesions, low/moderate-grade branch-
duct IPMNs) occurred also significantly more often after
the age of 50 years (13 vs 2, p<0.0004). The diagnostic
yield of potentially relevant lesions was not different
between screening protocols using annual MRI with EUS
(n=98) or annual MRI with EUS every 3rd year (n=198)
and between IAR screened at intervals of 12 months
(n=180) or IAR that decided to be screened at
≥24 months intervals (n=30).
Conclusions It appears safe to start screening for
PDAC in IAR of non-CDKN2a FPC families at the age of
50 years. MRI-based screening supplemented by EUS at
baseline and every 3rd year or when changes in MRI
occur appears to be efficient.
INTRODUCTION
During a consensus conference in 2003 the atten-
dees recommended to perform pancreatic cancer
(pancreatic ductal adenocarcinoma, PDAC) screen-
ing under research protocol conditions for those
individuals who are deemed to be at high risk of
developing the disease.1 Some years later the atten-
dees to a subsequent consensus conference (Cancer
of the Pancreas Screening study (CAPS) summit in
2011) stated that individuals at risk (IAR) for the
development of PDAC should be screened, if eligi-
ble for potential surgical treatment.2 3 A multidisci-
plinary approach combining screening and
treatment at high-volume centres, preferably within
research studies, was recommended. Individuals
with an at least 5–10-fold increased risk for PDAC,
such as members of familial pancreatic cancer
(FPC) families with at least two affected first-degree
relatives (FDRs), are felt to be good candidates for
Significance of this study
What is already known on this subject?
▸ Individuals at risk (IAR) of familial pancreatic
cancer (FPC) are recommended to participate in
prospective screening programmes to detect
early pancreatic cancer or its high-grade
precursor lesions.
▸ The age at which screening should be initiated
is uncertain. Almost all programmes start
screening at the age of 40–45 years or 10 years
below the youngest age of onset in the family.
▸ Endoscopic ultrasound (EUS) and MRI are used
complementarily for pancreatic imaging in the
majority of screening programmes, but it is
unclear whether both are necessary at every
screening visit.
▸ The optimal intervals for follow-up imaging
need to be determined, although most experts
recommend annual imaging, if the pancreas is
normal at baseline screening.
What are the new findings?
▸ Screening of IAR for FPC rarely reveals
significant and potentially relevant pancreatic
lesions before the age of 50 years.
▸ MRI-based screening supplemented by EUS at
baseline and every 3rd year or when changes
in MRI occur appeared to be efficient.
▸ Screening intervals of 24 months may be
justified in IAR with an unremarkable pancreas
at baseline imaging.
How might it impact on clinical practice in
the foreseeable future?
▸ Raising the age and changing the screening
protocol can reduce the psychological distress
of IAR and the costs of FPC screening
programmes without losing efficiency.
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screening.1 2 For the vast majority of experts at the
CAPS-summit only the detection and surgical treatment of
T1N0M0 adenocarcinoma and the high-grade precursor lesions
pancreatic intraepithelial neoplasia 3 (PanIN3), main-duct intra-
ductal papillary mucinous neoplasia (IPMN) and branch-duct
(BD) IPMN with high-grade dysplasia was judged to be a
success of screening.2 Unfortunately, these lesions are asympto-
matic and still difficult to diagnose with the current imaging
procedures. Most centres currently consider screening based on
MRI with MR cholangiopancreatography (MRCP) and endo-
scopic ultrasonography (EUS) as the best approach to detect
small solid pancreatic tumours and IPMNs ≤1 cm in size as well
as irregularities of the pancreatic duct.3–15 Although high-grade
PanIN lesions cannot be detected reliably with the current
imaging methods, cystic lesions, consistent with the diagnosis of
BD-IPMNs, can be visualised in up to 42% of IAR of FPC
families.10
The age at which screening should be initiated and stopped is
uncertain.1 2 Most published programmes start screening at the
age of 40–45 years or 10 years below the youngest age of onset
in the family.3–15 The optimal intervals for follow-up imaging
also need to be determined. Most experts recommend annual
imaging, if the pancreas is normal at baseline screening.2
To identify the most effective protocol in the present study
we determined the prevalence of significant and potentially rele-
vant pancreatic lesions at the index examination and during
follow-up with regard to age and different screening protocols
in a large cohort of IAR for non-CDKN2a FPC.
CDKN2a-positive patients with FPC were not included, since




The national case collection for familial pancreatic cancer in
Germany (FaPaCa), the Leiden registry and the Madrid registry
were established in 1996, 1999 and 2009, respectively, to pro-
spectively collect FPC families.13 18–20 Screening results of
patient subgroups from the three centres, in particular MRI and
pathological findings, were already reported previously.8 16 17 20 21
As previously suggested2 22 the diagnosis of FPC was based on
the presence of two or more FDRs with a confirmed diagnosis
of PDAC, and without evidence of any other inherited tumour
syndrome. FPC families were included based on a three-
generation family pedigree and confirmation of all cancer diag-
noses in the family by review of medical and pathological
records, death certificates, and by revision of the pathology
slides whenever available. Members of families fulfilling the cri-
teria of FPC were offered mutation analyses of the BRCA1/2,
PALB2 and CDKN2a genes as previously described.17 23 24 All
IAR underwent BRCA1/BRCA2 and PALB2 mutation analyses
and the Marburg and Leiden cohorts also underwent CDKN2a
mutation analysis. Analysis of mismatch repair genes or STK11
genes was only performed when the family history was suspi-
cious for hereditary non-polyposis colorectal cancer (HNPCC)
or Peutz–Jeghers syndrome. ATM mutation analysis was not per-
formed on any of the IAR. IAR of familial atypical multiple
mole melanoma families with CDKN2a mutations were
excluded from the analysis to reduce heterogeneity, since the
development and precursor lesions of PDAC in this entity
appears to be different.16
All IAR from the above defined FPC families were offered
participation in board-approved PDAC screening programmes
that were conducted exclusively at the three participating
centres between July 2002 and May 2015. The following indivi-
duals were classified as IAR and encouraged to participate in
PDAC screening:
▸ FDRs of affected patients that are members of FPC families;
▸ Mutation carriers of a BRCA1/2 and PALB2 germline muta-
tion with at least one affected patient with PDAC in the
family, independent of the degree of relationship.
IAR were considered at high risk, if they were members of a
family with three or more affected relatives with PDAC, and at
moderate risk, if they were members of a family with two
affected FDRs (FDR is defined as a close blood relative which
includes the individual’s parents, full siblings or children).
IAR were selected for PDAC screening, if they provided
informed consent to participate in the study. Screening started
10 years before the youngest age of onset in the family or by the
age of 40 years, whichever occurred earlier.
Screening protocols
The surveillance programme at the Philipps University in
Marburg included annual screening with MRI with MRCP and
EUS between 2002 and 2010 (protocol 1). Based on our initial
analyses8 21 that revealed a relatively low diagnostic yield of
potentially relevant lesions, the screening protocol was modi-
fied. Since January 2011 follow-up imaging consisted of annual
MRI with MRCP and EUS every 3rd year or when suspicious
alterations were detected by MRI (protocol 2). If a suspicious
lesion was identified, imaging was repeated after 4 weeks, possi-
bly with EUS-guided fine needle aspiration cytology (FNAC).
In case the lesions detected by imaging had a high probability to
be malignant or premalignant, an interdisciplinary board discus-
sion took place to decide whether to follow-up or to resect.
The surveillance programme in Madrid included annual EUS
and MRI. IAR with pancreatic lesions suspicious to be premalig-
nant or malignant were discussed by a multidisciplinary pan-
creas committee. The team then decided, whether a more
intensive follow-up via imaging was necessary or whether
surgery was required.
IAR of FPC families at the Leiden University Medical Centre
were invited for an annual MRI with MRCP. Beginning in 2011,
EUS was also offered as an option in addition to annual MRI.
IAR with lesions suspicious for malignancy were additionally
imaged with EUS and CT within the subsequent 2–3 weeks. In
case the imaging workup was suggestive of malignancy, the IAR




EUS was in every institution performed by experienced endoso-
nographers. Radial or linear echoendoscopes (Pentax FG 32 UA
with a longitudinal 7.5 MHz and 5 MHz sector array (Pentax
Medical Europe Headquarters, Hamburg, Germany) in combi-
nation with a Hitachi EUB 525 ultrasound processor (Hitachi
Medical systems Europe, Zug, Switzerland) or Olympus
GF-UE160 with an Aloka ultrasound processor (Olympus
Europe, Hamburg)) and curvilinear (Olympus UCT/UCP 160
Olympus Europe, Hamburg, Germany) devices were used
according to the personal preference of the endosonographer.
Investigations were performed under conscious sedation with
midazolam or propofol. The examination of the pancreas fol-
lowed a standardised protocol according to institutional stan-
dard operating procedures.16 In case a relevant lesion or an
indeterminate lesion was identified, the lesion was described,
measured in two dimensions and video recorded.
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MRI (MRI+MR cholangiopancreatography)
MRI was performed using a 1.5 T or 3.0 T clinical MR scanner
(Magnetom Sonata, Siemens, Erlangen, Germany) in one
session. Axial T2-weighted as well as T1-weighted images with
and without contrast agent (Magnevist, Bayer Schering Pharma,
Berlin, Germany) were acquired. In addition, MRCP images
were acquired prior and after stimulation with secretin
(Secrelux, Sanochemia, Neuss, Germany). All MRIs were inde-
pendently reviewed by an experienced radiologist. Images were
analysed for focal lesions in the morphological T1-weighted and
T2-weighted images. The MRCP images were evaluated for
filling defects, duct dilatation, stenoses or duct interruption.
Lesions were classified as solid, cystic or indeterminate with or
without connection to pancreatic ducts. They were measured in
two dimensions and described according to shape, heterogeneity
and location.
Follow-up and treatment recommendations
In case the diagnostic workup was uneventful at baseline, a
follow-up examination was recommended to the IAR after
12 months. When a pancreatic lesion suspicious of malignancy
was identified in any of the imaging modalities, the findings
were reviewed by an interdisciplinary board consisting of sur-
geons, radiologists, gastroenterologists and pathologists to deter-
mine further management, either intensified surveillance
eventually including FNAC or surgery. Criteria to recommend
surgery were solid lesions, cystic lesions >30 mm, cystic lesions
<30 mm with a substantial solid component, indeterminate
lesions with irregular boundaries, positive or highly suspicious
EUS FNAC, significant change in size and morphology during
follow-up. In addition, pros and cons of surgical intervention
were discussed with IAR presenting with multiple small cystic
lesions, especially if a strong family history or a predisposing
mutation (eg, BRCA2) was present, since these small multiple
‘imaging’ BD IPMNs might be an indicator for concomitant
high-grade PanIN lesions neoplasia in the setting of FPC.25 IAR
with suspicious lesions who did not undergo surgery were fol-
lowed at 3-month intervals with EUS and MRI plus MRCP for
12 months. Further screening intervals depended on the
imaging results.
Surgery
IAR who agreed to a recommended surgical exploration or
insisted upon undergoing surgery due to carcinophobia under-
went primarily a limited pancreatic resection (either pylorus-
sparing partial duodenopancreatectomy or distal pancreatect-
omy), depending on the distribution of lesions in preoperative
imaging. Intraoperative ultrasonography was routinely used to
verify preoperatively imaged pancreatic lesions. After a limited
pancreatic resection (distal pancreatectomy or partial pancreati-
coduodenectomy) the specimen was sent for frozen section. In
IAR with the intraoperative diagnosis of high-grade PanIN and/
or IPMN or a PDAC based on frozen section, the procedure was
extended to total pancreatectomy.
Pathology
Pancreatic resection specimens were assessed by the local pathol-
ogists and by a reference pathologist (Kloeppel G, Institute for
General Pathology, Technical University Munich) with a special
expertise in pancreatic pathology. Pancreatic lesions were classi-
fied according to Detlefsen et al26 and Hruban et al.27
Outcomes considered success of screening
Histologically verified PDAC, PanIN3 lesions and IPMNs with
high-grade dysplasia were considered as true significant lesions fol-
lowing the suggestions of the CAPS summit.2 In addition, multifo-
cal PanIN2 (>10) lesions in association with BD-IPMNs with low
or moderate dysplasia and/or atypical flat lesions (AFL) and higher-
grade pancreatic neuroendocrine tumour (pNET>G1) were
judged to be health relevant for the patient and thus classified as
potentially relevant lesions.
Statistics
Descriptive statistics of the relatives who enrolled were com-
piled. Variables included age, gender, number of relatives with
PDAC, earliest age of onset in the family and underlying germ-
line mutations. The age of diagnosis of PDAC was retrieved
from the three-generation pedigrees and divided into 10-year
categories. Early age of onset was defined as the occurrence of
PDAC prior to the age of 50 years in a family. Significant lesions
were defined as the presence of histologically verified PDAC,
PanIN3 or IPMN with high-grade dysplasia. Potentially relevant
lesions were defined as histologically verified multifocal PanIN2
lesions with/without BD-IPMN with low-grade and moderate-
grade dysplasia and/or AFL and pNET. To compare the age of
the IAR undergoing prospective screening with that of their
youngest affected relative, we classified our subjects as to
whether they were younger, in the same 5-year age range, or
older than the youngest affected relative.
The number of patient years is the number of IARs multiplied
by the median number of years in screening. The calculation of
events per patient years was performed by dividing the number
of events by the number of patient years.
The χ2 test, Fisher’s exact test, t test and Wilcoxon rank sum
test were performed for categorical and numerical variables,
where appropriate, to compare patient characteristics.
Two-tailed p values <0.05 were considered to be statistically sig-
nificant. Analyses were performed using Prism V.6 GraphPad
Software.
RESULTS
Between July 2002 and June 2015 a total of 253 Caucasian IAR
(210 Marburg, 30 Madrid, 13 Leiden) completed at least the
baseline screening with a median of 3 (range 1–11) examination
visits. The 253 IAR underwent a total of 813 MRI and 450
EUS, including FNAC in five IAR. The screened IAR cohort
included 115 men (median age 48.5 years) and 138 women
(median age 48 years). Ninety-six (38%) individuals were high-
risk IAR from families with at least three affected family
members (FPC3), 140 (55%) were moderate-risk IAR from
families with at least two affected FDR (FPC2) and 17 (7%)
IAR had predisposing germline mutations (3 BRCA1, 8 BRCA2,
6 PALB2) with at least 1 affected FDR. Demographics of IAR
are shown in table 1.
Of the 253 IAR, 89 (35%) had prevalent abnormal findings at
baseline imaging, in the majority small cystic lesions (90%).
Another 45 (18%) IAR developed lesions, also mostly cystic,
during a median follow-up of 28 (range 3–152) months. Thus,
prospective screening identified pancreatic lesions in 134 (53%)
IAR. Of those 125 were cystic, 3 solid and 6 indeterminate. The
remaining 119 (47%) IAR had unremarkable imaging results at
baseline and during follow-up as described above. Characteristics
of pancreatic lesions identified are summarised in table 2.
No complications related to the contrast-enhanced MRI were
observed and all IAR that received an EUS tolerated the
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procedure well and were discharged from hospital on the day of
the procedure.
Evaluation of imaging results by the multidisciplinary team
and counselling of IAR resulted in surgical intervention in 21
IAR, for 10 IAR after initial screening and for 11 during
follow-up. The majority of these IAR had multiple small
imaging BD-IPMN (n=12), the remaining IAR indeterminate
(n=6) or solid lesions (n=3). In 16 IAR surgery was recom-
mended, whereas 5 IAR insisted to undergo histological clarifi-
cation of the pancreatic lesion(s) after counselling because of
carcinophobia. These 21 IAR underwent 6 total pancreatec-
tomies, 11 distal pancreatic resections and 4 partial pancreatico-
duodenectomies. There was no perioperative mortality.
Histopathological analysis identified six (2%) IAR with signifi-
cant lesions (two PDAC (stage I and IIb), three PanIN3, one
IPMN with high-grade dysplasia) as recently defined at the
CAPS summit.2 These included one PDAC (UICC stage IIB)
diagnosed in a patient who, for personal reasons, omitted two
scheduled screening visits after an initial imaging evaluation that
revealed no pathological findings in MRI or EUS. Another nine
IAR had potentially relevant lesions, including eight IAR with
multifocal PanIN2 lesions with or without BD-IPMN and/or
AFL and one IAR with a 12 mm pNET G2. The remaining six
IAR had either serous cystadenomas up to 40 mm in size (n=3)
or focal fibrosis with PanIN1b lesions (n=3) (table 3, see online
supplementary table S1). The diagnostic yield in the whole
cohort for potential relevant lesions was thus 5.9% (n=15/253),
and for histopathological significant lesions 2% (n=6/253).
Given a median follow-up of 28 (range 3–152) months, the inci-
dence for histologically verified significant lesions and PDAC
was 1 per 83 patient years and 1 per 250 patient years, respec-
tively. Despite one IAR, who discontinued the screening for
more than 2 years, none of the other 252 IAR developed a
PDAC during surveillance that was not picked up by the screen-
ing programme. There was no excess of other cancers among
IARs, only 2 of 253 IAR developed other cancers (1 breast
cancer, 1 cholangiocarcinoma) during the surveillance period.
The median age of IAR with pancreatic lesions was 51 years
ranging from 28 years to 81 years. Lesions were identified signifi-
cantly more often in IAR above the age of 45 years (p<0.0001).
However, no histopathological significant lesions (PDAC, PanIN3
and high-grade IPMN) were detected in IAR below the age of 50
years (table 4). Potentially relevant lesions (multifocal PanIN2
with low-grade IPMN and/or AFL, pNET) also were detected sig-
nificantly more often in IAR over the age of 50 years (13 vs 2,
p<0.001, table 4). There was no significant difference between
moderate-risk (FPC2) and high-risk IAR (FPC3). This was also
true for IAR with known germline mutations such as BRCA2.
Even in the 45 families with a low age of PDAC onset
(<50 years) and 25 families with a potential anticipation
Table 2 Characteristics of pancreatic lesions in IAR (n=134)
Parameter
All IAR with lesions
(n=134)






Type of lesion:* cystic/solid/indeterminate 125/3/6 83/1/5 42/2/1
Cystic lesions <10 mm 121 (90%) 80 (90%) 41 (91%)
Cystic lesions >10 mm 4 (3%) 3 (3.4%) 1 (2.2%)
Solid lesions 3 (2.2%) 1 (1.1%) 2 (4.4%)
Indeterminate lesions 6 (4.5%) 5 (5.6%) 1 (2.2%)
IAR with surgery 21 (16%) 10 (11%) 11 (24%)
Potentially relevant histology† 15/21 (71%) 7/10 (70%) 8/11 (73%)
Significant histology‡ 6/21 (29%) 3/10 (30%) 3/11 (27%)
*As determined by MRI and EUS.
†Includes 2 PDAC, PanIN3, IPMN with high-grade dysplasia; multifocal PanIN2±BD-IPMN±AFL, IPMN with low/moderate-grade dysplasia, pNET.
‡Only includes PDAC, PanIN3 and IPMN with high-grade dysplasia.
AFL, atypical flat lesion; BD, branch duct; EUS, endoscopic ultrasonography; IAR, individuals at risk; IPMN, intraductal papillary mucinous neoplasia; PanIN, pancreatic intraepithelial
neoplasia; PDAC, pancreatic ductal adenocarcinoma; pNET, pancreatic neuroendocrine tumour.











Median age (range), years at screening start 48 (25–81) 48 (28–71) 48 (26–81) 46 (25–70)
Gender (M/F) 115/138 43/53 68/72 4/13
Examination visits median/range 853 3 (1–11) 339 3 (1–11) 461 3 (1–11) 53 2 (1–9)
Number MRI/MRCP median/range 813 2 (1–11) 327 3 (1–11) 433 2 (1–11) 53 2 (1–9)
Number EUS median/range 450 1 (0–8) 139 1 (0–7) 280 1 (0–8) 31 1 (1–4)
Pancreatic lesions 134 (52.9%) 50 (52.1%) 74 (52.8%) 10 (59%)
IAR with significant lesions* 6 (2%) 3 (3.1%) 2 (1.4%) 1 (5.9%)
IAR with potentially relevant lesions† 15 (5.9%) 8 (8.3%) 4 (2.9%) 3 (17.6%)
*Includes PDAC, PanIN3 and IPMN with high-grade dysplasia.
†Also includes multifocal PanIN2, BD-IPMN with low/moderate dysplasia±AFL and pNET.
AFL, atypical flat lesion; BD, branch duct; EUS, endoscopic ultrasonography; FPC, familial pancreatic cancer; IAR, individuals at risk; IPMN, intraductal papillary mucinous neoplasia;
MRCP, MR cholangiopancreatography; PanIN, pancreatic intraepithelial neoplasia; PDAC, pancreatic ductal adenocarcinoma; pNET, pancreatic neuroendocrine tumour.
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phenomenon, lesions were not diagnosed at a significantly earlier
age (median age 48 years, range 28–71 years and median age 50
years, range 28–72 years, respectively). The age of IAR with his-
tologically verified lesions is shown in table 3.
Although regular screening was recommended to IAR every
12 months, 30 of 253 (11.9%) IAR decided to extend their
screening intervals to 24 months (20 IAR) or 36 months (10
IAR) for personal reasons. As mentioned above a female patient
who missed the regular 12 months screening two times in a row
was diagnosed with PDAC stage IIB 26 months after the last
screening visit that revealed no pathological findings in MRI or
EUS. This was the only IAR (1/30, 3.3%) in whom a significant
pancreatic lesion was missed due to an extended screening inter-
val >12 months.
The present study included a change of the screening protocol
in the Marburg cohort (for 210 IAR) over time. Between 2003
and 2010 follow-up examination visits included MRI plus EUS
every 12 months (protocol 1). As of January 2011 follow-up
examination visits consisted of annual MRI, but included EUS
only every 3 years or whenever a suspicious alteration occurred
during MRI follow-up (protocol 2). Ninety-eight IAR were
examined with protocol 1 and 175 IAR with protocol 2,
whereas 63 of these IAR were screened with both protocols
over the complete study period. This protocol change did not
result in a significant change of the diagnostic yield since pan-
creatic lesions were detected in 47 (48%) IAR in protocol 1 and
73 (42%) IAR in protocol 2 (p=0.37, table 5). The detection of
histologically confirmed potentially relevant pancreatic lesions
was also not different (5 IAR in protocol 1 vs 6 IAR in protocol
2, p=0.53).
DISCUSSION
The International Cancer of the Pancreas Screening Consortium
(CAPS) recommended PDAC screening for IAR of FPC families
to detect relevant pancreatic lesions, although the underlying
evidence to support this recommendation is restricted to level 3
evidence.2 More evidence is needed regarding the age to initiate
screening, screening intervals and the management of










IAR with PALB2 or
BRCA2 mutations
(n=3)
PDAC 2 53*, 68+ 1 1
pNET 1 48^ 1
Multifocal PanIN2+PanIN3 3 52*, 64*, 69* 1 2
BD-IPMN with HGD 1 52+ 1
Multifocal PanIN2+ BD-IPMN with LGD/MGD±AFL 6 47+, 54+, 57, 58*, 61, 70* 1 4 1
Multifocal PanIN2 2 53°, 67+ 1 1
Focal fibrosis+PanIN1b 3 49^, 54°, 60° 1 2
Serous cystadenoma 3 42°, 61°, 61° 2 1
Superscripts indicate previous references that reported imaging and pathological results of IAR: +-17; *-16, 17; ^-17, 20; °-8, 16, 17.
FPC2, two affected first-degree relatives; FPC3, at least three affected relatives.
AFL, atypical flat lesion; BD-IPMN, branch-duct type intrapapillary mucinous neoplasia; FPC, familial pancreatic cancer; IAR, individuals at risk; LGD/MGD/HGD, low-grade,
moderate-grade, high-grade dysplasia; PanIN, pancreatic intraepithelial neoplasia; PDAC, pancreatic ductal adenocarcinoma; pNET, pancreatic neuroendocrine tumour.


















































<40 16/48 (33%) 13 (27%) 3 (6%) 0/48 (0%) 0 (0%) 0 (0%) 0/48 (0%) 0 (0%) 0 (0%)
≥40 118/205 (57%) 76 (37%) 42 (20%) 6/205 (2.9%) 3 (1.45%) 3 (1.45%) 15/205 (7.3%) 6 (2.9%) 9 (4.4%)
<45 36/98 (37%) 26 (27%) 10 (10%) 0/98 (0%)** 0 (0%) 0 (0%) 0/98 (0%) 0 (0%) 0 (0%)
≥45 98/155 (63%)* 63 (41%) 35 (22%) 6/155 (3.8%) 3 (1.9%) 3 (1.9%) 15/155 (9.7%) 6 (3.9%) 9 (5.8%)
<50 67/152 (44%) 46 (30%) 21 (14%) 0/152 (0%)** 0 (0%) 0 (0%) 2/152 (1.3%) 0 (0%) 2 (1.3%)
≥50 67/101 (66%) 43 (42%) 24 (24%) 6/101 (6%) 3 (3%) 3 (3%) 13/101 (12.9%)*** 6 (5.9%) 7 (7%)
<55 86/183 (47%) 56 (31%) 30 (16%) 3/183 (1.6%) 1 (0.5%) 2 (1.1%) 7/183 (3.8%) 1 (0.5%) 6 (3.3%)
≥55 48/70 (68%) 33 (47%) 15 (21%) 3/70 (4.2%) 2 (2.8%) 1 (1.4%) 8/70 (11.4%) 5 (7.1%) 3 (4.3%)
<60 107/217 (49%) 70 (32%) 37 (17%) 3/217 (1.4%) 1 (0.45%) 2 (0.95%) 9/217 (4.1%) 1 (0.4%) 8 (3.7%)
≥60 27/36 (75%) 19 (53%) 8 (22%) 3/36 (8.3%) 2 (5.6%) 1 (2.7%) 6/36 (16.6%) 5 (13.9%) 1 (2.7%)
Total with
lesions
134/253 (52.9%) 89 (35%) 45 (18%) 6/253 (2.4%) 3 (1.2%) 3 (1.2%) 15/253 (5.9%) 6 (2.3%) 9 (3.6%)
*p=0.0001; **p<0.001; ***p=0.0004.
†Includes PDAC, PanIN3, high-grade IPMN.
‡Potentially relevant lesions: includes PDAC, multifocal PanIN2/3 lesions with/without low/moderate dysplastic BD-IPMN or AFL, pNET.
AFL, atypical flat lesion; BD, branch duct; IAR, individuals at risk; PanIN, pancreatic intraepithelial neoplasia; IPMN, intraductal papillary mucinous neoplasia; PDAC, pancreatic ductal
adenocarcinoma; pNET, pancreatic neuroendocrine tumour.
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asymptomatic pancreatic lesions in IARs. The present report
provides the largest prospective baseline and follow-up screen-
ing study of a well defined cohort of 253 CDKN2a-negative
asymptomatic IAR from FPC families. The screening was based
on MRI plus MRCP and EUS imaging, as these are currently
considered the best modalities to detect early pancreatic neopla-
sias.4–15 In the present study 53% (134/253) of IAR revealed
mostly cystic pancreatic lesions. This high prevalence of cystic
lesions in IAR is in line with three previous MRI and EUS-based
prospective studies that reported pancreatic lesions in 33–45%
of IAR.9 10 15
In the recent CAPS summit,2 there was a disagreement over
the age to initiate screening. Fifty-one per cent of experts voted
to recommend starting screening at age 50 years. However,
most published programmes started screening at the age of
40–45 years or 10 years before the youngest age of onset in the
family.3–15 Screening age is a relevant issue with regard to the
psychological burden of IARs as well as the costs for the health
system, but the published data on the age of onset of PDAC in
the setting of FPC are not conclusive. The pancreatic cancer
genetic epidemiology consortium of the USA reported an
average age of onset of 68 years which was the same age as for
sporadic cases.28 In contrast, the German FaPaCa registry
reported a median age of onset of 63 years with 16% of patients
younger than 50 years, which was about 5 years younger than
reported age of onset for sporadic cases in Germany.21 In addi-
tion, a European study reported the phenomenon of anticipa-
tion in 80% of FPC families, implying that the age of PDAC
onset diminishes in consecutive generations of IAR.29 In the
present study imaging lesions of the pancreas were detected sig-
nificantly more often in IAR over the age of 45 years (37% vs
63%, p=0.0001), both at baseline screening and during
follow-up. This is line with the studies of Canto et al10 and
Ludwig et al11 who also detected pancreatic lesions significantly
more often in IAR older than 50 years or 55 years based on an
EUS/MRI approach. In the present study all six IAR with histo-
logically proven PDAC, PanIN3 and high-grade IPMNs were
>50 years. In addition, potentially relevant lesions such as mul-
tifocal PanIN2 lesions with or without low-grade to moderate-
grade BD-IPMNs and/or AFL also occurred significantly more
often at an age over 50 years (13 vs 2, p=0.0004).
The results of the present study strongly suggest that the
lower age limit of starting screening for PDAC in IAR of FPC
families can be raised to 50 years. This observation is supported
by the analysis of recent prospective multidisciplinary FPC
screening programmes in the USA and Europe that screened a
total of 1132 IAR from FPC families.4–15 In the total cohort
significant lesions were detected in 2.9% of the screened IAR
(n=22 PDAC, 11 PanIN3 or high-grade IPMN), and only 3%
of these lesions (n=1/33) were detected before the age of
50 years.4–15 The total yield of screening compares positively
with the 2% total yield described in our study. In terms of effec-
tiveness of the presented screening programme, the yield of
PDAC (0.8%) and significant precursor lesions (2.4%) was low.
However, if surgical removal of multifocal PanIN2 and multifo-
cal BD-IPMNs is regarded as beneficial, the diagnostic yield
rises to 5.9% (15/253) and the presented surveillance strategy
could be considered effective. However, at the present time we
do not know if patients with these lesions will ever progress to
PDAC, so that a final statement would be premature.
The recent CAPS consensus summit, as well as several other
authors suggested that annual MRI plus MRCP and EUS are
currently the best imaging tests for the detection of significant
PDAC precursor lesions.2 7 8 10 11 15 The present study also
confirms the effectiveness of this screening approach. The
present study is the first that used and compared two screening
protocols (MRI+EUS every 12 months (protocol 1) versus
annual MRI+EUS every 3 years or when suspicious alterations
develop in follow-up MRIs (protocol 2)). There was no signifi-
cant difference between the two screening protocols with regard
to imaging yield and yield of histologically confirmed poten-
tially relevant pancreatic lesions (five IAR protocol 1 vs six IAR
protocol 2, p=0.53). Thus, we suggest that adding EUS to MRI
at baseline and subsequently only every 3rd year or when a sus-
picious lesion develops in follow-up MRIs is sufficient for the
screening of IAR from FPC families. Since EUS is stressful due
to the required sedation, time- consuming and costly, confirma-
tion of these findings in other long-term surveillance studies
would be beneficial for PDAC screening.
The optimal intervals for follow-up screening need also to be
determined. Most experts recommend that imaging should be
repeated every 12 months, if the pancreas shows no lesions at
baseline screening.2 The present study had the opportunity to
evaluate the effect of screening intervals of more than
12 months by chance. Due to personal reasons 30 (11.9%) of
253 IAR in the present study missed one or more scheduled
annual visits and had at least one screening interval of
24 months (20 IAR) or even 36 months (10 IAR). Of these 30
IAR, only one IAR (3.3%) developed a PDAC 26 months after
normal baseline imaging and none of the other 29 IAR showed
significant progression at the next follow-up that required
surgery. Although the presented data do not provide enough sta-
tistical power to come up with a definitive conclusion, it may be
suggested that in IAR with an unremarkable pancreas at baseline




IAR with potentially relevant
pancreatic lesions* Missed PDAC
All IAR 210 120 (57%) 11 1
IAR in protocol 1† 98‡ 47 (48%) 5 0
IAR in protocol 2§ 175‡ 73 (42%) 6 0
IAR with screening intervals ≥24 months 30/210 (14.3%) 17 (57%) 1/30 (3%) 1
*Includes PDAC, multifocal PanIN2/3 lesions with/without BD-IPMN or AFL, pNET.
†Protocol 1 included MRI+MRCP+EUS every 12 months.
‡63 IAR were also screened with the other protocol during the complete study time.
§Protocol 2 consisted of annual MRI+MRCP. EUS was performed at baseline and then every 3 years or in case of suspicious MRI findings.
AFL, atypical flat lesion; BD, branch duct; EUS, endoscopic ultrasonography; FaPaCa, the national case collection for familial pancreatic cancer in Germany; IAR, individuals at risk;
IPMN, intraductal papillary mucinous neoplasia; MRCP, MR cholangiopancreatography; PanIN, pancreatic intraepithelial neoplasia; PDAC, pancreatic ductal adenocarcinoma; pNET,
pancreatic neuroendocrine tumour.
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imaging, 2 year screening intervals are sufficient and safe.
Therefore, we now consider extending the screening intervals to
24 months in IAR with an unremarkable pancreas at baseline
screening. This approach is also underscored by the results of a
quantitative analysis of the timing of the genetic evolution of
PDAC, that indicate a time span of at least one decade between
the occurrence of the cancer initiating mutation and cancer for-
mation, providing a broad window of opportunity for the early
detection of pancreatic cancer.30 Recent studies suggest,
however, that once a PDAC becomes detectable, clinical progres-
sion from low-stage to advanced-stage disease is rapid.31 Thus,
intensifying screening at baseline by using MRI plus EUS to
exclude the presence of clinically detectable PDAC, and to
de-escalate screening intensities and intervals thereafter appears
as an option to be discussed.
The present study has some limitations. First, the majority of
IAR (83%) were included from one centre resulting in some
selection bias. Second, a definitive diagnosis of imaged pancrea-
tic lesions was rarely verified by histopathology, since most IAR
with lesions (84%) received no surgical treatment. Third,
examiner-dependent results of EUS and interpretation of MRI
images among the multiple physicians involved may have influ-
enced the results of the present study. Fourth, due to the lack of
evidence-based practice guidelines for recommending surgery,
each of the three participating centres used an institution-
specific individualised approach to recommend surgical treat-
ment. Compared with some previous studies, the number of
pancreatic resections and histologically analysed pancreatic
lesions was relatively low.3 5 6 Fifth, the results are only applic-
able for IARs from FPC families without CDKN2a mutations
that have a lower risk than CDKN2a-positive pedigrees.
In summary, starting screening of IAR from non-CDKN2a
FPC families at the age of 50 years appears to be safe and effec-
tive. A screening protocol with annual MRI plus MRCP and
EUS every 3 years or whenever alterations are detected during
MRI follow-up might be as effective as annual MRI plus EUS
screening. Screening intervals of 24 months may be justified in
IAR with an unremarkable pancreas at baseline imaging. The
presented data should be considered during counselling to
reduce the psychological distress of IAR and the costs of FPC
screening programmes.
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